SUBSCRIBE: Print / eNewsletter
ctDNA Reveals Genomic Differences of mRCC During First-, Second-Line Therapy
This video examines a new study that looked at genomic alterations in the circulating tumor DNA of patients with metastatic RCC during first- and second-line therapies.
Hitting Prostate Cancer Where It Hurts: Maximizing Control of Osseous Metastases
Enhanced control of osseous metastases with both systemic life-extending therapies and bone-support medications has meaningful clinical impact for prostate cancer patients.
Metastatic Adrenocortical Carcinoma With a Prolonged Response to Mitotane
Adrenocortical carcinoma is a rare disease, with an annual incidence rate ranging from 0.5 to 2.0 cases per million individuals.